Metagenomi Inc (NASDAQ:MGX) has seen 1.9 million shares traded in the last trading session. The company, currently valued at $97.53M, closed the last trade at $3.11 per share which meant it lost -$0.13 on the day or -4.17% during that session. The MGX stock price is -309.65% off its 52-week high price of $12.74 and 48.23% above the 52-week low of $1.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 8.25 million shares traded. The 3-month trading volume is 1.62 million shares.
The consensus among analysts is that Metagenomi Inc (MGX) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.58.
Metagenomi Inc (NASDAQ:MGX) trade information
Sporting -4.17% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the MGX stock price touched $3.11 or saw a rise of 36.79%. Year-to-date, Metagenomi Inc shares have moved -69.88%, while the 5-day performance has seen it change -25.54%. Over the past 30 days, the shares of Metagenomi Inc (NASDAQ:MGX) have changed 65.16%. Short interest in the company has seen 0.27 million shares shorted with days to cover at 0.6.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 55.57% from current levels. The projected low price target is $7.0 while the price target rests at a high of $7.0. In that case, then, we find that the current price level is -125.08% off the targeted high while a plunge would see the stock gain -125.08% from current levels.
Metagenomi Inc (MGX) estimates and forecasts
Figures show that Metagenomi Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -26.25% over the past 6 months, with this year growth rate of 87.73%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 15.35%.
5 analysts offering their estimates for the company have set an average revenue estimate of 9.46M for the current quarter. 2 have an estimated revenue figure of 6.25M for the next ending quarter. Year-ago sales stood 12.4M and 11.16M respectively for this quarter and the next, and analysts expect sales will shrink by -23.70% for the current quarter and 15.35% for the next.
MGX Dividends
Metagenomi Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Sep 30, 2024 , the former fund manager holds about 0.47% shares in the company for having 177.21 shares of worth $0.55 million while later fund manager owns 164.94 shares of worth $0.51 million as of Sep 30, 2024 , which makes it owner of about 0.44% of company’s outstanding stock.
